GLI1 and basal cell carcinoma: This mutation, from a drug-resistant basal cell carcinoma patient, dramatically diminished GLI1–SUFU binding (Kd = 3,800 ± 1,600 nM, a ∼250-fold decrease in affinity; Fig 8B).